Alphamab/3D Medicines PD-L1 Antibody Approved for US Trial

Suzhou Alphamab and 3D Medicines (Sichuan) have received approval from the US FDA to begin clinical trials of KN035, a PD-L1 bi-specific immunotherapy. The two companies partnered on the molecule earlier this year: Alphamab discovered and developed the product, while 3D will be in charge of the clinical trials and commercialization. KN035 is a fusion protein of a PD-L1 single domain antibody and Fc. More details.... Share this with colleagues: // //